Monkeypox ― exotic infection outbreak or a new global challenge to global Health system?

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

BACKGROUND: Monkeypox, a zoonotic disease caused by an orthopoxvirus, results in a smallpox-like or a chickenpox-like disease. Monkeypox in human was first diagnosed in 1970 in the Democratic Republic of the Congo and subsequently has spread to other regions of Africa (primarily West and Central). In 2003 the first monkeypox outbreak occurred outside of Africa in USA. The latest outbreak of monkeypox in May 2022 is characterized by the simultaneous involvement of several hundred people. The appearance of cases outside of Africa highlights the risk for geographical spread and the global relevance of the disease requiring the epidemiologic studies and the search for effective methods of prevention and therapy.

AIMS: To summarize and systematize the results of studies on the epidemiology, diagnosis, clinical picture, the role of vaccination and treatment of monkeypox, including taking into account the last outbreak of the disease in May 2022 in non-endemic regions.

MATERIALS AND METHODS: A systematic literature search was conducted in MEDLINE (Ovid), MEDLINE (PubMed), and the Google Scholar database published up to May 31, 2022, using the keywords "monkeypox" or "monkeypox virus" or "smallpox human monkeys". We primary selected 112 abstracts. After removing duplicates and irrelevant articles, 48 full-text articles have been selected. After reviewing the full-text article versions, 15 articles were excluded due to highly specialized biological topics, poor study design, quality of results, or their unavailability. Ultimately, this review included 33 articles, in addition to which 6 founding and supporting websites were cited.

RESULTS: Monkeypox cases among humans have been on the rise since the 1970s, primarily in endemic areas. The median age at the time of treatment increased from 4 (1970s) to 21 (2010–2019). Since 2003, the spread of monkeypox outside Africa has been noted, associated with the importation of infected animals, migration and tourism. Transmission to humans occurs through close contact with an infected animal (70%), a person or material contaminated with the virus. Monkeypox presents with fever, vesicular rash, and lymphadenopathy lasting 2 to 4 weeks. Mortality is associated with the development of complications and is 10.6% for the Central African clade compared to 3.6% for the West African clade. There have been no deaths outside of Africa. Our review shows an escalation of monkeypox cases, especially in endemic Africa and spread to other countries, which is likely due to the discontinuation of smallpox vaccination, which provided cross-protection against monkeypox. Unfortunately, smallpox vaccination is contraindicated in immunocompromised individuals, despite the availability of recommended vaccines. The effectiveness of existing antiviral drugs (tecovirimate and brincidofovir) has been little studied in humans.

CONCLUSION: The weakening of population immunity, associated with the cessation of vaccination against smallpox, created the prerequisites for the outbreaks of monkeypox, including in non-endemic areas. Surveillance and detection programs are important tools for understanding the ever-changing epidemiology of this disease. In light of the emergence of cases outside of Africa, the potential for human-to-human transmission of the virus, the public health significance of monkeypox should not be underestimated.

About the authors

Igor S. Dolgopolov

Tver State Medical University

Email: irdolgopolov@gmail.com
ORCID iD: 0000-0001-9777-1220
SPIN-code: 4312-9786

MD, Dr. Sci. (Med.)

Russian Federation, Tver

Maksim Yu. Rykov

Tver State Medical University; N.A. Semashko National Research Institute of Public Health

Author for correspondence.
Email: wordex2006@rambler.ru
ORCID iD: 0000-0002-8398-7001
SPIN-code: 7652-0122

MD, Dr. Sci. (Med.), Assistant Professor, Research Associate

Russian Federation, Tver; 12, Bldg. 1, Vorontsovo Pole street, Moscow, 105064

Zhanna V. Khamtsova

V.P. Avaev Center for specialized types of medical care

Email: hamtsova@yandex.ru
ORCID iD: 0000-0002-7642-098X

MD

Russian Federation, Tver

References

  1. Bunge EM, Hoet B, Chen L, et al. The changing epidemiology of human monkeypox ― a potential threat? A systematic review. PLoS Negl Trop Dis. 2022;16(2):e0010141. doi: 10.1371/journal.pntd.0010141
  2. Fine PE, Jezek Z, Grab B, Dixon H. The transmission potential of monkeypox virus in human populations. Int J Epidemiol. 1988; 17(3):643–650. doi: 10.1093/ije/17.3.643
  3. Jezek Z, Khodakevich LN, Wickett JF. Smallpox and its post-eradication surveillance. Bull World Health Organ. 1987;65(4):425–434.
  4. Von Magnus P, Andersen EK, Petersen KB, Birch-Andersen AA. Pox-like disease in cynomolgus monkeys. Acta Pathol Microbiol Scand. 2009;46(2):156–176. doi: 10.1111/j.1699-0463.1959.tb00328.x
  5. Alakunle E, Moens U, Nchinda G, Okeke MI. Monkeypox virus in Nigeria: infection biology, epidemiology, and evolution. Viruses. 2020;12(11):1257. doi: 10.3390/v12111257
  6. Cohen J. Exotic diseases: is an old virus up to new tricks? Science. 1997;277(5324):312–313. doi: 10.1126/science.277.5324.312
  7. Mwanbal PT, Tshioko KF, Moudi A, et al. Human monkeypox in Kasai Oriental, Zaire (1996–1997). Euro Surveill. 1997;2(5):33–35. doi: 10.2807/esm.02.05.00161-en
  8. World Health Organization. Disease outbreak news; multi-country monkeypox outbreak in non-endemic countries [Internet]. [cited 2021 Nov 17]. Available from: https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON388.
  9. Sale TA, Melski JW, Stratman EJ. Monkeypox: an epidemiologic and clinical comparison of African and US disease. J Am Acad Dermatol. 2006;55(3):478–481. doi: 10.1016/j.jaad.2006.05.061
  10. Hoff NA, Doshi RH, Colwell B, et al. Evolution of a disease surveillance system: an increase in reporting of human monkeypox disease in the Democratic Republic of the Congo, 2001–2013. Int J Trop Dis Health. 2017;25(2):IJTDH.35885. doi: 10.9734/IJTDH/2017/35885
  11. Kalthan E, Tenguere J, Ndjapou SG, et al. Investigation of an outbreak of monkeypox in an area occupied by armed groups, Central African Republic. Med Mal Infect. 2018;48(4):263–268. doi: 10.1016/j.medmal.2018.02.010
  12. Beer EM, Rao VB. A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy. PLoS Negl Trop Dis. 2019;13(10):e0007791. doi: 10.1371/journal.pntd.0007791
  13. Vaughan A, Aarons E, Astbury J, et al. Two cases of monkeypox imported to the United Kingdom, September 2018. Euro Surveill. 2018;23(38):1800509. doi: 10.2807/1560-7917.ES.2018.23.38.1800509
  14. Huhn GD, Bauer AM, Yorita K, et al. Clinical characteristics of human monkeypox, and risk factors for severe disease. Clin Infect Dis. 2005;41(12):1742–1751. doi: 10.1086/498115
  15. Jezek Z, Grab B, Szczeniowski M, et al. Clinico-epidemiological features of monkeypox patients with an animal or human source of infection. Bull World Health Organ. 1988;66(4):459–464.
  16. Yinka-Ogunleye A, Aruna O, Dalhat M, et al. Outbreak of human monkeypox in Nigeria in 2017–2018: a clinical and epidemiological report. Lancet Infect Dis. 2019;19(8):872–879. doi: 10.1016/S1473-3099(19)30294-4
  17. Yong SE, Ng OT, Ho ZJ, et al. Imported monkeypox, Singapore. Emerg Infect Dis. 2020;26(8):1826–1830. doi: 10.3201/eid2608.191387
  18. Brown K, Leggat PA. Human monkeypox: current State of Knowledge and implications for the future. Trop Med Infect Dis. 2016;1(1):8. doi: 10.3390/tropicalmed1010008
  19. Rimoin AW, Mulembakani PM, Johnston SC, et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci USA. 2010;107(37):16262–16267. doi: 10.1073/pnas.1005769107
  20. Nolen LD, Osadebe L, Katomba J, et al. Introduction of monkeypox into a community and household: risk factors and zoonotic reservoirs in the Democratic Republic of the Congo. Am J Trop Med Hyg. 2015;93(2):410–415. doi: 10.4269/ajtmh.15-0168
  21. World Health Organization. Disease outbreak news; multicountry monkeypox outbreak in non-endemic countries [Internet]. [cited 2021 Nov 17]. Available from: https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON385.
  22. Jezek Z, Szczeniowski M, Paluku KM, Mutombo M. Human monkeypox: clinical features of 282 patients. J Infect Dis. 1987; 156(2):293–298. doi: 10.1093/infdis/156.2.293
  23. Diaz-Cánova D, Moens UL, Brinkmann A, et al. Genomic sequencing and analysis of a novel human cowpox virus with mosaic sequences from North America and old world orthopoxvirus. Front Microbiol. 2022;13:868887. doi: 10.3389/fmicb.2022.868887
  24. Karem KL, Reynolds M, Braden Z, et al. Characterization of acute-phase humoral immunity to monkeypox: use of immunoglobulin M enzyme-linked immunosorbent assay for detection of monkeypox infection during the 2003 North American outbreak. Clin Diagn Lab Immunol. 2005;12(7):867–872. doi: 10.1128/CDLI.12.7.867-872.2005
  25. Townsend MB, MacNeil A, Reynolds MG, et al. Evaluation of the tetracore orthopox BioThreat (R) antigen detection assay using laboratory grown orthopoxviruses and rash illness clinical specimens. J Virol Methods. 2013;187(1):37–42. doi: 10.1016/j.jviromet.2012.08.023
  26. Di Giulio DB, Eckburg PB. Human monkeypox: an emerging zoonosis. Lancet Infect Dis. 2004;4(1):15–25. doi: 10.1016/S1473-3099(03)00856-9
  27. Centers for Disease Control and Prevention Prevention (CDC). Update: multistate outbreak of monkeypox ― Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. MMWR Morb Mortal Wkly Rep. 2003;52(25):589–590.
  28. World Health Organization. Technical advisory group on human monkeypox report of a WHO meeting; Geneva, Switzerland, 11–12 January 1999 (accessed on 17 May 2016) [Internet]. [cited 2021 Nov 17]. Available from: http://www.who.int/csr/resources/publications/viral/whocdscsraph995.pdf?ua=1.
  29. Avert HIV and Aids in Sub-Saharan Africa regional overview. (accessed on 29 October 2016) [Internet]. [cited 2021 Nov 17]. Available from: http://www.avert.org/professionals/hiv-around-world/sub-saharan-africa/overview.
  30. Le Page M. Monkeypox: key questions answered. New Sci. 2022;254(3388):8–9. doi: 10.1016/S0262-4079(22)00914-9
  31. Nalca A. Zumbrun EE. ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile. Drug Des Dev Ther. 2010;4:71–79. doi: 10.2147/DDDT.S3687
  32. World Health Organization. Summary report on first, second and third generation smallpox vaccines. (accessed on 1 November 2016) [Internet]. [cited 2021 Nov 17]. Available from: http://www.who.int/immunization/sage/meetings/2013/november/2_Smallpox_vaccine_review_updated_11_10_13.pdf.
  33. Petersen BW, Damon IK, Pertowski CA, et al. Clinical guidance for smallpox vaccine use in a post-event vaccination program. MMWR Recomm Rep. 2015;64(RR-02):1–26.
  34. Mucker EM, Goff AJ, Shamblin JD, et al. Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (smallpox) antimicrob. Agents Chemother. 2013;57(12):6246–6253. doi: 10.1128/AAC.00977-13
  35. National Center for Biotechnology Information. PubChem compound summary for CID 16124688, tecovirimat [Internet]. [cited 2021 Nov 17]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Tecovirimat.
  36. Hutson CL, Kondas AV, Mauldin MR, et al. Pharmacokinetics and efficacy of a potential smallpox therapeutic, brincidofovir, in a lethal monkeypox virus animal model. mSphere. 2021;6(1):e00927-20. doi: 10.1128/mSphere.00927-20
  37. Centers for Disease Control and Prevention. Monitoring people who have been exposed [Internet]. [cited 2021 Nov 17]. Available from: https://www.cdc.gov/poxvirus/monkeypox/clinicians/monitoring.html.

Copyright (c) 2022 Eco-vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies